7.87
-6.23 (-44.18%)
| Penutupan Terdahulu | 14.10 |
| Jumlah Dagangan | 559,118 |
| Harga / Jualan (P/S) | 1.94 |
| Harga / Buku (P/B) | 36.54 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,921.38% |
| EPS Cair (TTM) | -0.640 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -75.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 108.28% |
| Nisbah Semasa (MRQ) | 1.03 |
| Aliran Tunai Operasi (OCF TTM) | -34.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.34 M |
| Pulangan Atas Aset (ROA TTM) | -67.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -221.66% |
AISkor Stockmoo
| Nilai 30% | -4.2 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Keuntungan lemah. Kecairan jangka pendek nipis. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | -3.6 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Berita info | NA |
| Wang Pintar 20% | 1.9 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih +75.12% daripada saham dalam pemfailan 13F terkini: 35 pemegang menambah, 19 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +171.0% dari 31 Aug hingga 30 Oct 2026, 7.6 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Tiada isyarat jelas daripada sokongan dan rintangan. info | |
| Skor Akhir | -2.43 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cue Biopharma, Inc. | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CUE | - | - | - | 36.54 |
| TRML | 1 B | - | - | 4.76 |
| CTMX | - | - | - | 1.55 |
| HURA | - | - | - | 4.84 |
| GANX | - | - | - | 4.54 |
| PRTA | - | - | - | 1.56 |
|
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.35% |
| % Dimiliki oleh Institusi | 19.45% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tetragon Partners Gp Ltd | 30 Jun 2026 | 93,819 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 65.83%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 35 | 3,280,294 |
| Berkurang | 19 | 254,853 |
| Baharu | 17 | 2,454,175 |
| Dijual habis | 8 | 221,057 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 862,798 | 7.6 |
| 15 Oct 2026 | 792,553 | 3.7 |
| 30 Sep 2026 | 702,198 | 1.1 |
| 15 Sep 2026 | 332,105 | 2.4 |
| 31 Aug 2026 | 318,420 | 1.8 |
| 14 Aug 2026 | 327,442 | 1.6 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone… |
| 28 Sep 2026 | Yahoo Finance |
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate… |
| 25 Sep 2026 | Yahoo Finance |
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12… |
| 22 Sep 2026 | Yahoo Finance |
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill. |
| 21 Sep 2026 | Yahoo Finance |
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria. |
| 20 Sep 2026 | Yahoo Finance |
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable… |
Isyarat Terkini corak lilin dan silang EMA
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |